Entera Bio, Ltd. (ENTX) stock prices surged by a massive 24.76% as of the market closing on June 17th, 2021, bringing the price per share up to USD$5.19 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock inch up by another 0.19%, bringing it up to USD$5.20.
Patent Granted
The company announced on June 17th, 2021 that it had been granted a patent titled “Methods and Compositions for Oral Administration of Protein’s” by the European Patent office. The patent secures a marketspace for the companies PTH formulations that are currently in advanced clinical stages for osteoporosis and hypoparathyroidism.
Safeguarding Intellectual Property
The critical patent covers leading PTH treatment products that are based on the company’s platform technology. The newly granted patent, in conjunction, with a myriad of other patents that cover oral formulations and target indications, facilitate the provision of robust protection for ENTX’s intellectual property. Besides the EU patent, the company has been granted strategic patents from countries including, but not limited to, USA, China, Japan, Australia, and New Zealand.
Scope of Patent
Especially promising was the recent news of the successful completion of the none-month time window during which the patent could have been challenged. The company is keen to consolidate its position as a market leader in the oral delivery of proteins in the wake of the upcoming six-month BMD result reports from the Phase 2 study. Phase 2 is scheduled for the second quarter of fiscal 2021. The company also has plans to potentially initiate a pivotal Phase 3 study next year, designed to evaluate the company’s oral PTH treatment of osteoporosis.
About ENTX
ENTX is an established leader in the development of large molecule therapeutics that are delivered orally, with the company targeting areas with significant unaddressed medical needs. Penetration is highest in markets where the use of injectable therapies is limited for various reasons, including cost, convenience, or compliance issues for patients. The company is spearheading efforts to address standard technical challenges of poor absorption high variability, and the inability to effectively ensure delivery of large molecules to the intended locations in the body.
Future Outlook for ENTX
Armed with this ground-breaking development, ENTX is poised to continue its trajectory of success by preparing itself to successfully execute the market proliferation of its patented treatment. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.
